GPx develops remote monitoring solutions for chronic disease management, starting with heart failure patients. The company utilizes proprietary predictive algorithms, termed "Bloodless Blood Tests," trained on a unique digital and blood biomarker database. This technology provides continuous, actionable NT-proBNP monitoring without requiring invasive procedures.
Funding
$9.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Managing chronic diseases like heart failure often requires frequent monitoring of blood biomarkers, traditionally done through invasive blood draws. These procedures can be inconvenient for patients, increase healthcare costs, and may delay timely treatment adjustments.
Solution
GPx has developed Bloodless Blood Tests, which are predictive algorithms trained on a proprietary database of digital and blood biomarkers, to remotely monitor chronic diseases. Their initial product, CardioID, enables continuous, non-invasive tracking of NT-proBNP levels in heart failure patients. This allows clinicians to make timely and informed treatment decisions based on real-time data, without the need for frequent blood draws. The technology aims to provide accuracy comparable to implantable devices, but without the need for invasive procedures.
Target Audience
The primary target audience includes clinicians and healthcare providers specializing in heart failure management, as well as hospitals and organizations focused on remote patient monitoring solutions.
Features
- Predictive algorithms trained on a proprietary database of digital and blood biomarkers
- Non-invasive remote monitoring of NT-proBNP levels for heart failure patients
- Continuous data tracking for timely clinical decision-making
- Clinician dashboard for accessing patient data and trends
- Algorithms designed to correlate with traditional blood tests